#ASH20: Bain ex­ecs step in to po­si­tion a some­what bat­tered and bruised Sy­ros with a new clin­i­cal can­di­date and enough mon­ey to charge ahead

Sy­ros $SYRS CEO Nan­cy Si­mon­ian had more than da­ta to dis­cuss dur­ing the vir­tu­al ASH ses­sions this week­end.

On top of a new cut of the da­ta for their lead can­cer drug, SY-1425, a trio of Bain ex­ecs has stepped in to set up a ma­jor new in­fu­sion of funds along with a new prod­uct ac­qui­si­tion aimed at beef­ing up the pipeline as they shoot for the prover­bial “ful­ly in­te­grat­ed” sta­tus of a com­mer­cial play­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER